| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 54 | 2023 | 431 | 5.820 |
Why?
|
| HIV-1 | 23 | 2022 | 203 | 2.120 |
Why?
|
| Anti-HIV Agents | 14 | 2022 | 63 | 1.800 |
Why?
|
| Vaginosis, Bacterial | 9 | 2007 | 16 | 0.990 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2020 | 60 | 0.890 |
Why?
|
| Lactobacillus | 4 | 2008 | 15 | 0.780 |
Why?
|
| Vagina | 7 | 2008 | 31 | 0.730 |
Why?
|
| RNA, Viral | 9 | 2019 | 44 | 0.720 |
Why?
|
| Continuity of Patient Care | 2 | 2020 | 17 | 0.700 |
Why?
|
| Mass Screening | 2 | 2020 | 161 | 0.700 |
Why?
|
| Humans | 76 | 2023 | 22932 | 0.670 |
Why?
|
| Electronic Health Records | 2 | 2022 | 64 | 0.630 |
Why?
|
| Adult | 42 | 2020 | 6931 | 0.620 |
Why?
|
| Female | 51 | 2023 | 12958 | 0.610 |
Why?
|
| HIV Antibodies | 6 | 2022 | 14 | 0.600 |
Why?
|
| Patient Compliance | 2 | 2018 | 146 | 0.580 |
Why?
|
| Reminder Systems | 1 | 2018 | 1 | 0.560 |
Why?
|
| Appointments and Schedules | 1 | 2018 | 12 | 0.550 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 121 | 0.510 |
Why?
|
| Viral Load | 12 | 2020 | 70 | 0.510 |
Why?
|
| Melioidosis | 1 | 2015 | 3 | 0.470 |
Why?
|
| Burkholderia pseudomallei | 1 | 2015 | 3 | 0.470 |
Why?
|
| Travel | 1 | 2015 | 14 | 0.470 |
Why?
|
| Middle Aged | 28 | 2023 | 7915 | 0.450 |
Why?
|
| HIV | 5 | 2023 | 39 | 0.430 |
Why?
|
| Gardnerella vaginalis | 5 | 2008 | 5 | 0.420 |
Why?
|
| Mycoplasma hominis | 5 | 2008 | 5 | 0.420 |
Why?
|
| Male | 35 | 2023 | 12460 | 0.420 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 111 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 362 | 0.380 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2011 | 21 | 0.370 |
Why?
|
| Candidiasis, Vulvovaginal | 3 | 2007 | 3 | 0.360 |
Why?
|
| CD4 Lymphocyte Count | 13 | 2020 | 49 | 0.350 |
Why?
|
| HIV Antigens | 2 | 2022 | 12 | 0.350 |
Why?
|
| Polymerase Chain Reaction | 3 | 2005 | 112 | 0.330 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2002 | 42 | 0.330 |
Why?
|
| Lamivudine | 2 | 2019 | 7 | 0.290 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 13 | 0.290 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2000 | 39 | 0.290 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 442 | 0.290 |
Why?
|
| Interleukin-8 | 2 | 2008 | 14 | 0.290 |
Why?
|
| Adolescent | 6 | 2019 | 1882 | 0.290 |
Why?
|
| Candida albicans | 1 | 2008 | 2 | 0.280 |
Why?
|
| Coronary Artery Disease | 3 | 2023 | 124 | 0.280 |
Why?
|
| Cytomegalovirus Infections | 2 | 2023 | 27 | 0.280 |
Why?
|
| Immunoglobulin G | 3 | 2023 | 67 | 0.280 |
Why?
|
| Candidiasis | 1 | 2008 | 17 | 0.270 |
Why?
|
| Cervix Uteri | 5 | 2002 | 12 | 0.270 |
Why?
|
| Trichomonas Infections | 1 | 2007 | 2 | 0.270 |
Why?
|
| Hyperlipidemias | 2 | 2004 | 17 | 0.260 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2004 | 8 | 0.260 |
Why?
|
| Urban Population | 2 | 2019 | 127 | 0.260 |
Why?
|
| Interleukin-2 | 2 | 2008 | 22 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2005 | 163 | 0.250 |
Why?
|
| Chicago | 6 | 2023 | 813 | 0.250 |
Why?
|
| Oxazines | 3 | 2019 | 5 | 0.240 |
Why?
|
| Antibodies, Viral | 5 | 2022 | 48 | 0.240 |
Why?
|
| Hepatitis C | 2 | 2023 | 42 | 0.230 |
Why?
|
| Drug Therapy, Combination | 6 | 2019 | 162 | 0.220 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2004 | 3 | 0.220 |
Why?
|
| Nevirapine | 2 | 2004 | 2 | 0.220 |
Why?
|
| Hydroxychloroquine | 1 | 2004 | 8 | 0.220 |
Why?
|
| Lipids | 1 | 2004 | 45 | 0.220 |
Why?
|
| AIDS Vaccines | 1 | 2004 | 2 | 0.220 |
Why?
|
| Insulin Resistance | 1 | 2004 | 48 | 0.210 |
Why?
|
| Immunity, Cellular | 2 | 2023 | 33 | 0.210 |
Why?
|
| Interleukin-12 | 1 | 2004 | 33 | 0.210 |
Why?
|
| Genitalia, Female | 5 | 2005 | 13 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 12 | 0.200 |
Why?
|
| Emergency Service, Hospital | 3 | 2023 | 253 | 0.200 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 22 | 0.200 |
Why?
|
| HIV-2 | 1 | 2022 | 8 | 0.190 |
Why?
|
| Vaccines | 1 | 2022 | 7 | 0.190 |
Why?
|
| Interleukin-6 | 2 | 2002 | 70 | 0.190 |
Why?
|
| Immunoassay | 1 | 2022 | 33 | 0.190 |
Why?
|
| Arginine | 1 | 2002 | 17 | 0.190 |
Why?
|
| Immunity | 1 | 2002 | 9 | 0.190 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2022 | 4 | 0.180 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 226 | 0.180 |
Why?
|
| beta Catenin | 1 | 2022 | 58 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 289 | 0.170 |
Why?
|
| Needlestick Injuries | 1 | 2000 | 1 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2000 | 6 | 0.170 |
Why?
|
| Liver Failure, Acute | 1 | 2000 | 5 | 0.170 |
Why?
|
| Occupational Exposure | 1 | 2000 | 17 | 0.170 |
Why?
|
| Receptors, IgG | 1 | 2020 | 7 | 0.170 |
Why?
|
| Genital Diseases, Female | 2 | 1997 | 5 | 0.160 |
Why?
|
| Dideoxynucleosides | 1 | 2000 | 1 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 36 | 0.160 |
Why?
|
| Wnt Proteins | 1 | 2020 | 21 | 0.160 |
Why?
|
| Glycoproteins | 1 | 2020 | 41 | 0.160 |
Why?
|
| HIV Core Protein p24 | 3 | 2018 | 10 | 0.160 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 30 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 5 | 0.160 |
Why?
|
| Biomarkers | 2 | 2023 | 474 | 0.150 |
Why?
|
| Program Development | 1 | 2019 | 44 | 0.150 |
Why?
|
| Zidovudine | 3 | 1999 | 13 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2019 | 102 | 0.150 |
Why?
|
| Vaginal Smears | 3 | 2007 | 11 | 0.140 |
Why?
|
| United States | 5 | 2023 | 1765 | 0.140 |
Why?
|
| Pilot Projects | 5 | 2019 | 370 | 0.140 |
Why?
|
| Thailand | 1 | 2018 | 9 | 0.140 |
Why?
|
| Proprotein Convertase 9 | 1 | 2017 | 2 | 0.140 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 5 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2022 | 94 | 0.140 |
Why?
|
| Coinfection | 1 | 2017 | 20 | 0.130 |
Why?
|
| Anticholesteremic Agents | 2 | 2011 | 14 | 0.130 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 42 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 168 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2018 | 147 | 0.130 |
Why?
|
| Censuses | 1 | 2016 | 8 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2011 | 47 | 0.120 |
Why?
|
| Simplexvirus | 2 | 2006 | 4 | 0.120 |
Why?
|
| Mexico | 1 | 2015 | 14 | 0.120 |
Why?
|
| Phylogeny | 1 | 2015 | 40 | 0.120 |
Why?
|
| Retrospective Studies | 7 | 2023 | 2995 | 0.120 |
Why?
|
| Cytokines | 4 | 2008 | 191 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2011 | 1493 | 0.110 |
Why?
|
| Neuroaspergillosis | 1 | 2015 | 2 | 0.110 |
Why?
|
| Brain Abscess | 1 | 2015 | 4 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 171 | 0.110 |
Why?
|
| Triazoles | 1 | 2015 | 28 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2015 | 34 | 0.110 |
Why?
|
| Complement System Proteins | 3 | 1998 | 5 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2016 | 2941 | 0.100 |
Why?
|
| AIDS Serodiagnosis | 1 | 1993 | 4 | 0.100 |
Why?
|
| Kidney Transplantation | 2 | 2006 | 113 | 0.100 |
Why?
|
| Double-Blind Method | 5 | 2011 | 373 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2019 | 126 | 0.100 |
Why?
|
| Choroiditis | 1 | 1992 | 1 | 0.100 |
Why?
|
| Pneumocystis Infections | 1 | 1992 | 1 | 0.100 |
Why?
|
| Pentamidine | 1 | 1992 | 2 | 0.100 |
Why?
|
| Aged | 8 | 2018 | 7449 | 0.100 |
Why?
|
| Measles | 1 | 1991 | 1 | 0.090 |
Why?
|
| Measles virus | 1 | 1991 | 1 | 0.090 |
Why?
|
| Acyclovir | 1 | 1991 | 4 | 0.090 |
Why?
|
| Retinitis | 1 | 1991 | 2 | 0.090 |
Why?
|
| Fluconazole | 1 | 1991 | 7 | 0.090 |
Why?
|
| Cryptococcosis | 1 | 1991 | 6 | 0.090 |
Why?
|
| Histoplasmosis | 1 | 1991 | 8 | 0.090 |
Why?
|
| Pandemics | 2 | 2023 | 206 | 0.090 |
Why?
|
| Meningitis | 1 | 1991 | 10 | 0.090 |
Why?
|
| Cholesterol, HDL | 3 | 2011 | 26 | 0.090 |
Why?
|
| Cholesterol, LDL | 3 | 2011 | 29 | 0.090 |
Why?
|
| Pregnancy | 2 | 2011 | 324 | 0.090 |
Why?
|
| Triglycerides | 3 | 2011 | 54 | 0.090 |
Why?
|
| Logistic Models | 2 | 2011 | 351 | 0.090 |
Why?
|
| Fatty Alcohols | 1 | 2011 | 5 | 0.090 |
Why?
|
| Medically Underserved Area | 1 | 2011 | 13 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 11 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2011 | 15 | 0.080 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 19 | 0.080 |
Why?
|
| Body Composition | 2 | 2002 | 66 | 0.080 |
Why?
|
| Postpartum Period | 1 | 2011 | 21 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2011 | 537 | 0.080 |
Why?
|
| Neutrophils | 1 | 2011 | 89 | 0.080 |
Why?
|
| HIV Seropositivity | 3 | 2019 | 50 | 0.080 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2009 | 11 | 0.080 |
Why?
|
| Young Adult | 3 | 2020 | 1653 | 0.080 |
Why?
|
| Cholesterol | 3 | 2004 | 57 | 0.080 |
Why?
|
| Pyomyositis | 1 | 2009 | 5 | 0.080 |
Why?
|
| Blastomyces | 1 | 2009 | 10 | 0.080 |
Why?
|
| Extremities | 1 | 2009 | 24 | 0.080 |
Why?
|
| Blastomycosis | 1 | 2009 | 19 | 0.070 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1999 | 14 | 0.070 |
Why?
|
| Pyridones | 2 | 2019 | 10 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 161 | 0.070 |
Why?
|
| Colony Count, Microbial | 2 | 2005 | 17 | 0.070 |
Why?
|
| DNA, Bacterial | 2 | 2005 | 37 | 0.070 |
Why?
|
| Calcinosis | 1 | 2008 | 43 | 0.070 |
Why?
|
| Vaginal Douching | 2 | 2005 | 3 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2020 | 100 | 0.070 |
Why?
|
| Piperazines | 2 | 2019 | 82 | 0.070 |
Why?
|
| Papanicolaou Test | 1 | 2007 | 8 | 0.070 |
Why?
|
| Cytological Techniques | 1 | 2007 | 14 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2007 | 20 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2004 | 1417 | 0.070 |
Why?
|
| Monocytes | 2 | 2005 | 38 | 0.070 |
Why?
|
| Papillomavirus Infections | 2 | 2005 | 16 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 2 | 2004 | 18 | 0.060 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 47 | 0.060 |
Why?
|
| Hepatitis | 1 | 2006 | 5 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 19 | 0.060 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 761 | 0.060 |
Why?
|
| Comorbidity | 1 | 2007 | 426 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 1046 | 0.060 |
Why?
|
| Gentian Violet | 1 | 2005 | 3 | 0.060 |
Why?
|
| Phenazines | 1 | 2005 | 4 | 0.060 |
Why?
|
| Incidence | 1 | 2007 | 624 | 0.060 |
Why?
|
| Dietary Supplements | 2 | 2002 | 53 | 0.060 |
Why?
|
| Virus Activation | 2 | 2022 | 10 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 30 | 0.060 |
Why?
|
| Trichomonas Vaginitis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2002 | 26 | 0.060 |
Why?
|
| HIV Wasting Syndrome | 2 | 2002 | 4 | 0.060 |
Why?
|
| Placebos | 2 | 2002 | 63 | 0.060 |
Why?
|
| Mycoplasma Infections | 1 | 2004 | 1 | 0.060 |
Why?
|
| HIV Long Terminal Repeat | 3 | 1999 | 17 | 0.060 |
Why?
|
| Antimalarials | 1 | 2004 | 6 | 0.060 |
Why?
|
| Candida | 1 | 2004 | 14 | 0.060 |
Why?
|
| Sample Size | 1 | 2004 | 17 | 0.060 |
Why?
|
| Fasting | 1 | 2004 | 22 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2004 | 48 | 0.050 |
Why?
|
| Virus Latency | 2 | 2022 | 14 | 0.050 |
Why?
|
| Injections, Intradermal | 1 | 2004 | 1 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 3 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 12 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2004 | 12 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2004 | 215 | 0.050 |
Why?
|
| Insulin | 1 | 2004 | 77 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 439 | 0.050 |
Why?
|
| Safety | 2 | 2002 | 34 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2004 | 103 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2008 | 577 | 0.050 |
Why?
|
| Virus Replication | 1 | 2003 | 43 | 0.050 |
Why?
|
| CD28 Antigens | 1 | 2003 | 5 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2003 | 11 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 24 | 0.050 |
Why?
|
| Skin | 1 | 2004 | 117 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2023 | 6 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2003 | 14 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2003 | 12 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 15 | 0.050 |
Why?
|
| Glycosylation | 1 | 2022 | 14 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 13 | 0.050 |
Why?
|
| Liver | 1 | 2004 | 135 | 0.050 |
Why?
|
| Antibodies | 1 | 2022 | 43 | 0.050 |
Why?
|
| Risk Factors | 4 | 2008 | 1971 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 35 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2022 | 50 | 0.050 |
Why?
|
| Etanercept | 1 | 2002 | 21 | 0.050 |
Why?
|
| Sexual Behavior | 2 | 2002 | 46 | 0.050 |
Why?
|
| Cell Count | 1 | 2002 | 72 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 40 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1999 | 8 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2002 | 18 | 0.050 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2002 | 6 | 0.050 |
Why?
|
| Food, Formulated | 1 | 2002 | 3 | 0.050 |
Why?
|
| Disease Progression | 3 | 2003 | 529 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 92 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 24 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 15 | 0.050 |
Why?
|
| Viral Matrix Proteins | 1 | 2001 | 4 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 17 | 0.040 |
Why?
|
| Mutation | 2 | 2019 | 330 | 0.040 |
Why?
|
| NF-kappa B | 2 | 1999 | 100 | 0.040 |
Why?
|
| HIV Seronegativity | 2 | 1998 | 18 | 0.040 |
Why?
|
| Biological Products | 1 | 2002 | 30 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2001 | 8 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2001 | 23 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2000 | 6 | 0.040 |
Why?
|
| Cell Separation | 1 | 2020 | 21 | 0.040 |
Why?
|
| Benzoxazines | 1 | 2000 | 3 | 0.040 |
Why?
|
| Alkynes | 1 | 2000 | 4 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2000 | 13 | 0.040 |
Why?
|
| Cell Line | 4 | 2005 | 242 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2000 | 32 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 45 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2000 | 73 | 0.040 |
Why?
|
| Fever | 1 | 2000 | 32 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2000 | 81 | 0.040 |
Why?
|
| Biological Factors | 1 | 1999 | 3 | 0.040 |
Why?
|
| Esophageal Diseases | 1 | 1999 | 4 | 0.040 |
Why?
|
| Thalidomide | 1 | 1999 | 7 | 0.040 |
Why?
|
| Ulcer | 1 | 1999 | 4 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 1999 | 3 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 163 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 1999 | 5 | 0.040 |
Why?
|
| Pneumococcal Infections | 1 | 1999 | 5 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2019 | 13 | 0.040 |
Why?
|
| DNA | 1 | 1999 | 94 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 9 | 0.030 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 1997 | 4 | 0.030 |
Why?
|
| Body Fluids | 1 | 1997 | 11 | 0.030 |
Why?
|
| Menstrual Cycle | 1 | 1997 | 19 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 1997 | 9 | 0.030 |
Why?
|
| Complement Pathway, Classical | 1 | 1996 | 1 | 0.030 |
Why?
|
| Viremia | 1 | 1996 | 7 | 0.030 |
Why?
|
| Environment Design | 1 | 2016 | 4 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 1412 | 0.030 |
Why?
|
| Social Segregation | 1 | 2016 | 6 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 1102 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 78 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2016 | 49 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2016 | 113 | 0.030 |
Why?
|
| Poverty | 1 | 2016 | 85 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1995 | 21 | 0.030 |
Why?
|
| Tablets | 1 | 2015 | 3 | 0.030 |
Why?
|
| Voriconazole | 1 | 2015 | 10 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 28 | 0.030 |
Why?
|
| Survival Analysis | 1 | 1995 | 226 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2011 | 462 | 0.030 |
Why?
|
| Recurrence | 1 | 1995 | 268 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1995 | 190 | 0.030 |
Why?
|
| Transcription, Genetic | 3 | 1999 | 95 | 0.030 |
Why?
|
| Therapeutic Irrigation | 3 | 1998 | 44 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1993 | 29 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1993 | 25 | 0.020 |
Why?
|
| Pneumocystis | 1 | 1992 | 1 | 0.020 |
Why?
|
| Eye | 1 | 1992 | 6 | 0.020 |
Why?
|
| Liver Function Tests | 2 | 2003 | 21 | 0.020 |
Why?
|
| Didanosine | 1 | 1992 | 3 | 0.020 |
Why?
|
| Papillomaviridae | 2 | 2005 | 15 | 0.020 |
Why?
|
| Measles Vaccine | 1 | 1991 | 1 | 0.020 |
Why?
|
| Ophthalmoscopy | 1 | 1991 | 1 | 0.020 |
Why?
|
| Eye Infections, Viral | 1 | 1991 | 3 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1991 | 18 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1991 | 20 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1991 | 58 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 1991 | 55 | 0.020 |
Why?
|
| Electric Impedance | 2 | 2002 | 24 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1991 | 96 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 2011 | 4 | 0.020 |
Why?
|
| Neutrophil Activation | 1 | 2011 | 5 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 64 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 99 | 0.020 |
Why?
|
| Prevalence | 1 | 1991 | 376 | 0.020 |
Why?
|
| Medication Therapy Management | 1 | 2009 | 3 | 0.020 |
Why?
|
| Medication Errors | 1 | 2009 | 12 | 0.020 |
Why?
|
| Pharmacists | 1 | 2009 | 16 | 0.020 |
Why?
|
| Lung Diseases, Fungal | 1 | 2009 | 9 | 0.020 |
Why?
|
| Nurses | 1 | 2009 | 41 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 29 | 0.020 |
Why?
|
| Quadriceps Muscle | 1 | 2009 | 25 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 2 | 1999 | 16 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 14 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 21 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 16 | 0.020 |
Why?
|
| Antigens, CD | 2 | 1999 | 49 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 801 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 521 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 1203 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1991 | 1021 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 1997 | 94 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 341 | 0.020 |
Why?
|
| Immunity, Mucosal | 1 | 2005 | 11 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 860 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2005 | 14 | 0.010 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2005 | 1 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2005 | 23 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2005 | 22 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2005 | 25 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 178 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 243 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 283 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2004 | 18 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 169 | 0.010 |
Why?
|
| Bilirubin | 1 | 2003 | 10 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2002 | 39 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2003 | 33 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 260 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 113 | 0.010 |
Why?
|
| Protein Structure, Quaternary | 1 | 2001 | 5 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2001 | 7 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 2001 | 3 | 0.010 |
Why?
|
| Virus Assembly | 1 | 2001 | 3 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2001 | 20 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 104 | 0.010 |
Why?
|
| Dimerization | 1 | 2001 | 20 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 59 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2002 | 45 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2001 | 63 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2001 | 125 | 0.010 |
Why?
|
| Enteral Nutrition | 1 | 2002 | 60 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2001 | 74 | 0.010 |
Why?
|
| Calgranulin A | 1 | 2001 | 5 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 142 | 0.010 |
Why?
|
| Weight Loss | 1 | 2002 | 121 | 0.010 |
Why?
|
| Body Weight | 1 | 2000 | 129 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2002 | 548 | 0.010 |
Why?
|
| Mycoplasma | 1 | 1999 | 2 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 1999 | 3 | 0.010 |
Why?
|
| Stomatitis, Aphthous | 1 | 1999 | 2 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1999 | 8 | 0.010 |
Why?
|
| Chemical Fractionation | 1 | 1999 | 4 | 0.010 |
Why?
|
| Solubility | 1 | 1999 | 18 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1999 | 11 | 0.010 |
Why?
|
| Immunization | 1 | 1999 | 12 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2000 | 481 | 0.010 |
Why?
|
| Pneumococcal Vaccines | 1 | 1999 | 4 | 0.010 |
Why?
|
| Hepatitis C Antibodies | 1 | 1998 | 4 | 0.010 |
Why?
|
| Transfusion Reaction | 1 | 1998 | 6 | 0.010 |
Why?
|
| Virus Integration | 1 | 1998 | 6 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1998 | 9 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1998 | 2 | 0.010 |
Why?
|
| Chemokine CCL4 | 1 | 1998 | 2 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 1998 | 8 | 0.010 |
Why?
|
| Vaginitis | 1 | 1998 | 3 | 0.010 |
Why?
|
| Chemokine CCL5 | 1 | 1998 | 9 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 1998 | 16 | 0.010 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1998 | 14 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 73 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 125 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1998 | 227 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1998 | 219 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1998 | 286 | 0.010 |
Why?
|
| Heating | 1 | 1997 | 4 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1997 | 9 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1997 | 21 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1997 | 7 | 0.010 |
Why?
|
| Vaccination | 1 | 1997 | 26 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2003 | 811 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 76 | 0.010 |
Why?
|
| CD55 Antigens | 1 | 1996 | 1 | 0.010 |
Why?
|
| CD59 Antigens | 1 | 1996 | 2 | 0.010 |
Why?
|
| Staphylococcal Protein A | 1 | 1996 | 2 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1996 | 3 | 0.010 |
Why?
|
| Membrane Cofactor Protein | 1 | 1996 | 2 | 0.010 |
Why?
|
| Virion | 1 | 1996 | 12 | 0.010 |
Why?
|
| Apoptosis | 1 | 1997 | 194 | 0.010 |
Why?
|
| Quality of Life | 1 | 1999 | 559 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1992 | 6 | 0.010 |
Why?
|